Diabetes Care in The Netherlands: - Novo Nordisk

More documents

Recommendations

Info

2 2Diabetes care in The Netherlands has reached a a high level of ofquality, but but there there is is still still opportunity for for further further improvementimprovementDiabetes care clearly improved in The NetherlandsSelected Care Groups– 1996-2010Diabetes care clearly improved in The NetherlandsSelected Care Groups – 1996-20107.5%1996Average HbA1c values now below target value7.1%2000-20076.7%2008Target value
33Further improving health of of diabetes patients may lead lead to to EUR 1.5 -EUR 2 B of 1.5-2 economic B of economic benefits benefits in 2020 in 2020Estimated Economic BenefitsEUR M , 20201.000-1.5001.500 – 2.000Fully disabled400-600Partially disabledPresenteeismAbsenteeismComments:Less medical costs fromreduction incomplicationsReduction of lost productivityMedical costs andproductivity benefitsSource: Booz & Company AnalysisBooz & Company 14 November 2011• Reduction in cost due toless complications• Reduction in inflow of newworking disabilities• Reduction of ab- andpresenteeism in line withreduction in complicationsPrepared for Novo Nordisk613
Page 6 and 7: SummaryDiabetes is a serious and de
Page 8: diabetes care. Extra compensation w
Page 11 and 12: ContentsSummarized findings and rec
Page 13: 11Diabetes is a major and underesti
Page 17 and 18: 22Recommendation 2: Engage employer
Page 19 and 20: 44Recommendation 4: Introduce condi
Page 21 and 22: Already more than 1M diabetes patie
Page 23 and 24: Costs of of complications and treat
Page 25 and 26: Number of patients reaches ~1.4M in
Page 27 and 28: Increase in lost productivity is dr
Page 29 and 30: Diabetes care clearly improved in t
Page 31 and 32: Better compliance can be stimulated
Page 37 and 38: Delaying complications saves medica
Page 39 and 40: LimitedLimitedcollaborationcollabor
Page 41 and 42: Individual quality incentives are l
Page 43 and 44: Recommendation 1: Insurer should in
Page 47 and 48: Labour shortage from late nineties
Page 49 and 50: However, curative and participative
Page 53 and 54: Non-compliance leads to severe comp
Page 55: Facilitated patient networks are su
Page 58 and 59: Recommendation 3:Facilitate network
Page 62 and 63: But new medication could add a lot
Page 64 and 65:
ContentsSummarized findings and rec
Page 66:
Booz & Company is a global manageme
show all

Diabetes Care in The Netherlands: - Novo Nordisk

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?